Literature DB >> 25695504

Efflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical isolates.

Guilian Li1, Jingrui Zhang2, Qian Guo3, Yi Jiang1, Jianhao Wei4, Li-li Zhao1, Xiuqin Zhao1, Jianxin Lu5, Kanglin Wan1.   

Abstract

Isoniazid (INH) and rifampicin (RIF) are the two most effective drugs in tuberculosis therapy. Understanding the molecular mechanisms of resistance to these two drugs is essential to quickly diagnose multidrug-resistant (MDR) tuberculosis and extensive drug-resistant tuberculosis. Nine clinical Mycobacterium tuberculosis isolates resistant to only INH and RIF and 10 clinical pan-sensitive isolates were included to evaluate the expression of 20 putative drug efflux pump genes and sequence mutations in rpoB (RIF), katG (INH), the inhA promoter (INH), and oxyR-ahpC (INH). Nine and three MDR isolates were induced to overexpress efflux pump genes by INH and RIF, respectively. Eight and two efflux pump genes were induced to overexpress by INH and RIF in MDR isolates, respectively. drrA, drrB, efpA, jefA (Rv2459), mmr, Rv0849, Rv1634, and Rv1250 were overexpressed under INH or RIF stress. Most efflux pump genes were overexpressed under INH stress in a MDR isolates that carried the wild-type katG, inhA, and oxyR-ahpC associated with INH resistance than in those that carried mutations. The expression levels of 11 genes (efpA, Rv0849, Rv1250, P55 (Rv1410c), Rv1634, Rv2994, stp, Rv2459, pstB, drrA, and drrB) without drug inducement were significantly higher (P < 0.05) in nine MDR isolates than in 10 pan-sensitive isolates. In conclusion, efflux pumps may play an important role in INH acquired resistance in MDR M. tuberculosis, especially in those strains having no mutations in genes associated with INH resistance; basal expression levels of some efflux pump genes are higher in MDR isolates than in pan-sensitive isolates and the basal expressional differences may be helpful to diagnose and treat resistant tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25695504      PMCID: PMC4335044          DOI: 10.1371/journal.pone.0119013

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

A number of mechanisms have been shown to be operative by which mycobacteria, especially Mycobacterium tuberculosis, develop resistance to anti-tuberculosis drugs. Mutations in target genes associated with the mode of action of these drugs have been considered the main mechanism for drug resistance in M. tuberculosis [1,2,3]. For example, >90% of rifampicin (RIF)-resistant M. tuberculosis isolates have at least one mutation in rpoB, which encodes the RNA polymerase subunit [1,4]. Of isoniazid (INH)-resistant isolates, 50–94% have at least one mutation in katG, which encodes catalase-peroxidase, 10–35% carry at least one mutation in the inhA promoter, and 10–40% carry at least one mutation in oxyR-ahpC [2,4,5,6,7,8]. Alternative mechanisms such as decreased cell wall permeability to drugs and active efflux pumping are likely to be important for conferring resistance in the isolates in which no target gene mutations are found [9,10,11,12,13]. M. tuberculosis has been studied for the presence and activity of a number of efflux pump genes and their encoded products. Most of the studies to date used laboratory strains and transferred hypothetical efflux genes into a heterologous host (Mycobacterium smegmatis or Mycobacterium bovis) and demonstrated that the overexpression of these genes increases resistance levels [11,12,13,14], whereas few studies investigated the relevance of active efflux in the drug resistance of clinical strains [15,16]. Some efflux pumps in drug-resistant M. tuberculosis are expressed at higher levels under drug stress [16,17]; however, low expression of efflux pump(s) from Mycobacterium in the absence of drug-induced stress has also been reported [18]. This study aimed to evaluate the expression of 20 putative efflux pump genes in multidrug-resistant (MDR) M. tuberculosis clinical isolates. These genes were annotated as probable/hypothetical drug efflux genes in the M. tuberculosis genome [19] and are available at the website of the Wellcome Trust Sanger Institute (www.sanger.ac.uk/Projects/M_tuberculosis/Gene_list/functional_classes/III.A.6.shtml). The expression of these 20 genes in MDR M. tuberculosis clinical isolates was examined previously, as was their contribution to RIF resistance in M. tuberculosis clinical isolates [20]. The study will further increase our understanding of the mechanism of active efflux in the INH and RIF resistance of M. tuberculosis and is the first investigation of the expressional differences between MDR clinical isolates and pan-sensitive clinical isolates.

Materials and Methods

Ethics statement

This study was approved by the ethics committee of the National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. All patients involved in the study provided written informed consent.

Antibiotics and chemicals

Middlebrook 7H9 broth and albumin-dextrose-catalase (ADC) supplement were purchased from Difco (Detroit, MI, USA). INH, RIF, ethambutol (EMB), streptomycin (STR), ofloxacin (OFX), kanamycin (KAN), capreomycin (CPM), amikacin (AK), carbonyl cyanide m-chlorophenylhydrazone (CCCP), and reserpine were purchased from Sigma-Aldrich (St. Louis, MO, USA). All solutions were prepared on the day of the experiment. Trizol was purchased from Invitrogen (Carlsbad, CA, USA). Alamar blue was obtained from AbD Serotec (Oxford, UK).

Bacterial strains and drug susceptibility testing

Nine MDR isolates with different mutations in katG, inhA, oxyR-ahpC, and rpoB; 10 pan-sensitive isolates; and H37Rv were included. Seven MDR isolates were from Tibet Province, and two MDR isolates and 10 pan-sensitive isolates were from Fujian Province, China. All of the clinical isolates were recovered from a sputum specimen of patients with pulmonary tuberculosis and confirmed as the Beijing family by Spoligotyping as previously described by Kamerbeek et al. [21]. The isolate profiles of drug susceptibility were evaluated by the proportional method using Lowenstein-Jensen slants with the following: INH, 0.2 μg/mL; RIF, 40 μg/mL; STR, 4 μg/mL; EMB, 2 μg/mL; KAN, 30 μg/mL; OFX, 2 μg/mL; CPM, 40 μg/mL [22]; and AK, 30 μg/mL [23]. Nine MDR isolates were resistant to only INH and RIF but were sensitive to the other six drugs, while the 10 pan-sensitive isolates were sensitive to all eight drugs above.

Determination of minimum inhibitory concentrations (MICs)

A microplate alamar blue assay was performed as previously described [24] to determine the MICs of INH and RIF of the 19 clinical isolates. H37Rv was used as a sensitive control. The effect of the efflux inhibitors CCCP and reserpine on the MICs of these antibiotics was also studied. Two-fold serial dilutions of INH or RIF were made directly in the wells including or excluding 0.5 μg/mL CCCP [12,17] or 5 μg/mL reserpine [17]. Drug concentrations included 0.001–128 μg/mL INH or 0.001–256 μg/mL RIF. All tests were conducted twice. The MIC was defined as the lowest drug concentration that prevented a color change. Isolates with MICs of INH <0.25 μg/mL and RIF ≤1 μg/mL were defined as being sensitive to INH and RIF, respectively [24].

RNA extraction and reverse transcription

All 19 M. tuberculosis strains were subcultured in 7H9 medium with ADC supplement, and collected for RNA extraction. For the nine MDR isolates, RIF and INH were added to these cultures individually at subinhibitory concentrations (half of the MIC), incubated at 37°C for 25 days, and collected for RNA extraction. Total bacterial RNA was isolated using Trizol reagent according to the manufacturer’s instructions. The quality and integrity of the total RNA was assessed using a nanophotometer (Implen, Munden, Germany) and agarose gel electrophoresis. After treatment with DNase I (amp grade; Invitrogen), the lack of DNA contamination of the RNA samples was confirmed by polymerase chain reaction (PCR) amplification of rpoB directly from RNA. The forward and reverse primers are listed in S1 Table. A 50-μL aliquot of the PCR mixture (Kangwei Biotechnology, Beijing, China) was used, and the PCRs were denatured at 94°C for 5 min and subjected to 35 cycles at 94°C for 30 s, 62°C for 30 s, and 72°C for 30 s, followed by a final extension at 72°C for 10 min. RNA (1.5 μg) was reverse transcribed according to the manufacturer’s recommendations (Transgen Bio-Technology Company, Beijing, China), and the thermal cycling conditions were as follows: 25°C for 10 min, 42°C for 60 min, and 85°C for 5 min. The cDNA was maintained at −20°C. Two cDNA preparations were made for each strain.

Quantification of gene expression using real-time quantitative PCR (qPCR)

The primers of the 20 genes are described in S2 Table. The assay was performed using a qPCR kit (Transgen Bio-Technology Company) in a CFX96 thermocycler (Bio-Rad Laboratories Inc., Hercules, CA, USA). Briefly, each 0.2-mL tube contained 10 μL 2× qPCR mix, 3 pmol each primer, 10 ng cDNA, and RNase-free water to a final volume of 20 μL. The thermal cycling conditions were as follows: 50°C for 2 min and 95°C for 8 min, then 45 cycles of denaturation at 94°C for 10 s, annealing at 59°C for 15 s, and extension at 72°C for 20 s, and the last step consisted of a melting curve analysis (65–95°C). The fold change in the expression of genes under drug stress in nine MDR isolates was calculated by 2-ΔΔCT method of Livak and Schmittgen [25]. When compared with the non-exposed control genes showing expression levels above 1 were considered to be increased; equal to or above four were considered to be overexpressed [25,26,27,28]. The expression levels of 19 isolates without drug stress was caculated by 2-ΔCT method. The difference in threshold cycle (ΔCT) values were obtained by subtracting the CT value of polA from the CT value obtained for each gene. The ΔΔCT values were obtained by subtracting the ΔCT value obtained for each gene without drug inducement from the ΔCT value of genes induced by INH/RIF stress. qPCR was performed three times for each gene of each cDNA, and a mean expression level of each gene of one isolate was obtained from two cDNA preparations. polA is a housekeeping gene that is expressed at a stable level in the isolates and can used as an internal invariant control. The expression levels of the 20 genes without drug inducement of the nine MDR isolates were compared with those of the 10 pan-sensitive isolates.

DNA extraction and sequencing analysis

Twenty strains cultured on solid Lowenstein-Jensen medium were harvested and killed by heating at 80°C for 90 min. The genomic DNA was extracted by the cetyltrimethylammonium bromide method. The sequences of genes including rpoB for RIF, katG and inhA regulator sequence, and oxyR-ahpC genes for INH (reported to carry major mutations associated with RIF and INH resistance) were analyzed by PCR and DNA sequencing. The sequences of the specific primers and the sizes of the amplicons are presented in S1 Table. The PCR conditions of four genes were identical and described in RNA extraction and reverse transcription section. Partial PCR products were characterized by DNA sequencing using the forward primers on an ABI Prism 3730 automated DNA sequencer (ABI Prism). The resulting DNA sequences were analyzed using the basic local alignment search tool (http://www.ncbi.nih.gov/BLAST), and the specific mutations in protein sequences of the individual isolates were identified.

Data analysis

SPSS 16.0 (SPSS Inc., Chicago, IL, USA) was used to perform Mann-Whitney test, and the difference was considered to be statistically significant when P < 0.05.

Results and Discussion

INH/RIF MICs and the effect of efflux pump inhibitors on INH/RIF MICs of pan-sensitive clinical isolates

As shown in Table 1, the INH MICs for the 10 pan-sensitive clinical isolates and H37Rv were 0.016–0.063 μg/mL, whereas the RIF MICs were 0.0078–0.25 μg/mL. No decreases in the INH and RIF MICs were observed in the presence of the efflux pump inhibitors CCCP (0.5 μg/mL) or reserpine (5 μg/mL) in these isolates, which supported the results of an earlier study [18].
Table 1

Minimum inhibitory concentrations (MICs) for isoniazid (INH) and rifampicin (RIF) in the absence or presence of efflux inhibitors and the number of genes overexpressed in nine multidrug-resistant (MDR) M. tuberculosis isolates.

Isolate no.MIC (μg/mL) of INH +Genes overexpressed under INH stressMIC (μg/mL) of RIF +Genes overexpressed under RIF stress
NoneCCCPRSPNoneCCCPRSP
CCDC0910344 2 drrA, efpA, jefA (Rv2459)646464no
CCDC05148444 drrA 256256256no
CCDC09078222 drrA, mmr >256 32 32 drrB
CCDC102231 0.25 0.25 drrA, drrB, efpA, Rv0849, jefA (Rv2459)128 64 64 no
CCDC100381 0.25 0.5 drrA, drrB, efpA, jefA (Rv2459)256 64 64 Rv1634
CCDC101381 0.25 0.125 drrA, drrB, efpA, jefA (Rv2459)646464no
CCDC10017>128128>128 drrA 32 16 32no
CCDC1014311 0.5 drrA, jefA (Rv2459)1 0.25 0.25 no
CCDC10219>128 64 16 drrA, drrB, efpA, jefA (Rv2459), Rv1250, Rv1634 32 4 32 drrB
CCDC103280.0310.0310.031ND0.06250.06250.0625ND
CCDC103300.0310.0310.031ND0.1250.1250.125ND
CCDC102010.0630.0630.063ND0.250.250.25ND
CCDC102310.0630.0630.063ND0.06250.06250.0625ND
CCDC102460.0630.0630.063ND0.1250.1250.125ND
CCDC102550.0630.0630.063ND0.00780.00780.0078ND
CCDC102610.0630.0630.063ND0.1250.1250.125ND
CCDC102930.0160.0160.016ND0.1250.1250.125ND
CCDC102380.0630.0630.063ND0.06250.06250.0625ND
CCDC102390.0310.0310.031ND0.06250.06250.0625ND
H37Rv0.0630.0630.063ND0.06250.06250.0625ND

CCCP, carbonyl cyanide m-chlorophenylhydrazone; RSP, reserpine; numbers in bold mean that the MIC decreased relative to the INH or RIF MIC without inhibitors. ND, not determined.

CCCP, carbonyl cyanide m-chlorophenylhydrazone; RSP, reserpine; numbers in bold mean that the MIC decreased relative to the INH or RIF MIC without inhibitors. ND, not determined.

INH/RIF MICs and the effect of efflux pump inhibitors on INH/RIF MICs of MDR clinical isolates

As demonstrated in Table 1, the INH MICs of nine MDR isolates varied from 1 to >128 μg/mL, whereas the RIF MICs varied from 1 to >256 μg/mL. Of the nine MDR isolates cultured in the presence of efflux pump inhibitors CCCP (0.5 μg/mL) or reserpine (5 μg/mL), four isolates (44.4%) and six isolates (66.7%) demonstrated a significant decrease in the INH MIC after CCCP and reserpine exposure, respectively. Additionally, six isolates (66.7%) and four isolates (44.4%) showed a decrease in the RIF MICs after exposure to CCCP and reserpine, respectively. Sensitivity to INH was fully restored (MIC <0.25 μg/mL) in one isolate (CCDC10138) after reserpine exposure, whereas the RIF sensitivity was fully restored (MIC ≤1 μg/mL) in an additional isolate (CCDC10143) after exposure to reserpine and CCCP. In total, the MICs of INH or RIF of nine MDR isolates except one were affected by CCCP and reserpine. Mann-Whitney test showed that the fold change of MIC of RIF or INH of MDR strains decreased by CCCP or reserpine were all significantly higher than pan-sensitive group (P values were all <0.05), suggesting that the INH and RIF resistance levels could be affected by efflux pump inhibitor exposure in resistant strains, which is consistent with the reports of Rodrigues et al. [27] and Escribano et al. [29]. Rodrigues et al [27] found that the INH MIC of one INH-induced M. bovis BCG strain was decreased four- and two-fold by the drug efflux inhibitors chlorpromazine and thioridazine, respectively, and the INH MICs of three INH-induced M. tuberculosis isolates decreased more than 32-fold. Escribano et al. [29] observed that the MIC of fluoroquinolones in four to seven of seven fluoroquinolone-resistant M. tuberculosis clinical isolates was decreased by inhibitors MC 207.110 (Phe-Arg-β-naphthylamide) and reserpine. A previous study reported that BALB/c mice treated with first-line drugs in combination with the efflux pump inhibitor verapamil could significantly reduce pulmonary colony-forming units after 1 and 2 months of treatment (P < 0.05) [30]. These results suggest that efflux pump inhibitors have a potential use in tuberculosis treatment.

Expression of efflux pump genes under INH or RIF stress in MDR isolates

As demonstrated in Tables 1 and 2, all nine MDR isolates had at least one gene that was overexpressed under INH or RIF stress. More strains were induced to overexpress efflux pump genes by INH than by RIF (nine vs. three), and more genes were induced by INH than by RIF (eight vs. two). Additionally, more drug efflux pumps were overexpressed in MDR isolates in which the INH or RIF MICs decreased more than four-fold after CCCP or reserpine exposure under INH or RIF stress.
Table 2

Differential expression of efflux pump genes under isoniazid or rifampicin stress in M. tuberculosis by real-time reverse transcription quantitative PCR.

Stress conditionGene No. of MDR isolates with different fold change (2-ΔΔCT value, n = 9)*
0-1-2-3->4-
Isoniazid drrA 00009
drrB 02124
efpA 00225
mmr 02241
emrB 26100
Rv0849 02421
mmpL13a 35100
mmpL13b 44100
Rv1250 03231
tap (Rv1258c)34200
P55 (Rv1410c)14220
Rv1634 02511
Rv2994 15300
stp 26100
jefA (Rv2459)00126
pstB 43200
Rv2456 27000
Rv2265 36000
Rv3239 45000
Rv1877 27000
Rifampicin drrA 45000
drrB 00342
efpA 06210
mmr 27000
emrB 35100
Rv0849 16200
mmpL13a 62100
mmpL13b 45000
Rv1250 35100
tap (Rv1258c)26100
P55 (Rv1410c)15300
Rv1634 01431
Rv2994 24300
stp 00630
jefA (Rv2459)25200
pstB 24300
Rv2456 45000
Rv2265 54000
Rv3239c 54000
Rv1877 35000

* genes showing expression levels >one-fold change were considered to be increased and ≥ four-fold change were considered to be overexpressed under INH/RIF stress.

Our analysis demonstrated that INH/RIF induced differential expression of some of these genes, see Table 2. drrA, drrB, mmr, efpA, jefA (Rv2459), Rv0849, Rv1634, and Rv1250 were overexpressed (more than four-fold change). drrABC is a putative doxorubicin-resistance operon in M. tuberculosis [19]. drrAB expressed in M. smegmatis conferred resistance to a broad range of clinically relevant antibiotics, including EMB, STR, norfloxacin, erythromycin, tetracycline, and chloramphenicol [11]. In this study, drrA was overexpressed in all nine MDR isolates induced by INH and zero MDR isolates induced by RIF, suggesting that drrA was one of the factors for INH resistance in M. tuberculosis. Pang et al. reported that drrA may be responsible for low-level resistance to RIF [20], which was not consistent with our results. drrB was up-regulated consistently upon INH/RIF treatment in only those MDR strains that showed a significant reduction in MIC with CCCP/reserpine in this study, suggesting that drrB plays an important role in INH/RIF resistance in M. tuberculosis. * genes showing expression levels >one-fold change were considered to be increased and ≥ four-fold change were considered to be overexpressed under INH/RIF stress. Previous reports indicated that the expression of efpA increased in response to isoniazid [16,31], thiolactomycin [32], isoxyl, tetrahydrolipstatin, and three compounds from the Southern Research Institute, Birmingham, AL, USA [33]. Fu [31] and Gupta et al. [16] showed that the induced efpA expression was 4- and 4.5-fold greater under INH stress, respectively, which was consistent with the results in our study. jefA (Rv2459) has been reported to respond to INH stress, and Gupta et al. found that the increased transcription of jefA (Rv2459) leads to increased resistance to EMB and INH in M. tuberculosis [16,17]. Mmr has been reported to mediate the efflux of different chemical classes and antibiotics [34]. Expression of the M. tuberculosis protein Mmr in M. smegmatis was shown to resistance to tetraphenylphosphonium, erythromycin, ethidium bromide, acriflavine, safranin O, and pyronin Y [35]. Gupta et al. [16] found that mmr had two-fold higher expression in two isolates under the INH-stressed condition and three-fold higher expression in three isolates under the levofloxacin-stressed condition. Rv1634 is a member of the major facilitator superfamily in M.tuberculosis, similar to many antibiotic resistance (efflux) proteins, including DTDP-glucose dehydratase from Streptomyces violaceoruber [19,36,37,38]. Rv1634 has been reported to decrease susceptibility to various fluoroquinolones when overexpressed in M. smegmatis and involve in norfloxacin and ciprofloxacin efflux [37]. Louw et al. reported that Rv1634 was upregulated in strains with a Beijing genotype after exposure to RIF for 24 h [30]. Balganesh et al. [34] reported that the efflux pump encoded by Rv0849 mediates the efflux of RIF and AK. Rv1250 is a probable drug-transport integral membrane protein having 579 amino acid (aa) and highly similar to the tetracenomycin C protein from Streptomyces glaucescen (32.9% identity in 517 aa overlap). Rv1250 is also similar to Rv3239C from M. tuberculosis (31.9% identity in 423 aa overlap) [19]. No further information on this protein has been reported. Together, these results indicate that more efflux pumps may respond to INH than RIF in M. tuberculosis. A possible explanation for this may be that INH exerts its bactericidal activity by attacking the cell wall mycolic acid after being converted to a range of oxygenated and organic toxic radicals by bifunctional bacterial enzyme catalase-peroxidase (KatG) [39,40], whereas RIF acts by arresting DNA-directed RNA synthesis in the cytoplasm of M. tuberculosis [41,42]. Efflux pumps are located in the membrane of M.tuberculosis [19,37,43]. While the cell wall of M.tuberculosis is attacked by non-lethal dose of INH, more efflux pumps or combinations thereof are induced to efflux INH to avoid M.tuberculosis being killed. In 10 pan-sensitive isolates, none of 20 genes were induced to overexpress by RIF and INH in our previous study [44], which was consistent with the results that no decreases in the INH and RIF MICs in the presence of the efflux pump inhibitors CCCP (0.5 μg/mL) or reserpine (5 μg/mL) in these isolates.

Efflux pump gene expression in MDR isolates carrying gene mutations

Mutations in drug target genes are still thought to be the principal mechanism of drug resistance. Three (CCDC09103, CCDC05148, and CCDC09078) of the nine MDR isolates carried mutations of katG 315 + rpoB 531. Two isolates (CCDC10038 and CCDC10223) carried mutations of katG 298 + inhA (-15) + rpoB 531. One isolate (CCDC10138) carried mutations of katG 222 + rpoB 531. One isolate (CCDC10017) carried mutations of ahpC (-10) + rpoB 490 + rpoB 531 + rpoB 559. One isolate (CCDC10143) carried mutations of inhA (-15) + rpoB 511 + rpoB 526. One isolate (CCDC10219) carried a deletion mutation that affected codons 516 and 517 of rpoB and had the wild-type katG, inhA promoter, and oxyR-ahpC (Table 3). Eight of nine MDR isolates overexpressed at least one efflux pump gene, suggesting that efflux pump genes may be involved in resistance to INH and RIF in addition to the mutations in related genes [45]. Isolate CCDC10219 carried a deletion mutation in rpoB and had the wild-type version of genes associated with INH resistance; most efflux pump genes (six genes) were overexpressed compared with those in other isolates under INH stress, suggesting that efflux pump gene expression was the major cause of INH resistance in this isolate.
Table 3

Characteristics of mutations of 9 MDR isolates.

Isolate no.Gene mutations
rpoB katG inhA oxyR-ahpC
CCDC09103531TCG-TTG315AGC-ACCwtwt
CCDC05148531TCG-TTG315AGC-ACCwtwt
CCDC09078531TCG-TTG315AGC-ACCwtwt
CCDC10223531TCG-TTG298TTG-TGG(-15)C-Twt
CCDC10038531TCG-TTG298TTG-TGG(-15)C-Twt
CCDC10138531TCG-TTG222GCG-GAGwtwt
CCDC10017531TCG-TTG,490CAG-CGG, 559ATC-ACCwtwt(-10)C-T
CCDC10143511CTG-CCG,526CAC-CAGwt(-15)C-Twt
CCDC10219CCA deleted in 76838–76840 (BX842574.1)wtwtwt

wt, wild type.

wt, wild type.

The differences in drug efflux pump gene expression between MDR isolates and pan-sensitive isolates

The quantification results of the expression levels of 20 genes in nine MDR isolates and 10 pan-sensitive isolates are shown in S3 Table. In seven MDR strains CCDC09103, CCDC09078, CCDC10138, CCDC10143, CCDC10223, CCDC10017, and CCDC05148, gene Rv2265 showed the lowest expression levels from 0.014 to 0.246, and jefA (Rv2459) showed the highest expression levels from 8.744 to 33.063 except that efpA showed the highest expression of 6.329 in strain CCDC05148. In MDR strain CCDC10038 and CCDC10219, Rv3239c showed the lowest expression levels which were 0.242 and 0.174, respectively, and drrA showed the highest expression levels which were 6.493 and 65.983, respectively. The mean expression levels of efpA, Rv1250, jefA (Rv2459), and drrA in MDR isolates were all higher than 5.0 without any drug inducement. Of ten pan-sensitive clinical isolates, drrA showed the highest expression levels from 1.493 to 5.919 in eight isolates, while efpA shown highest expression level of 10.801 in strain CCDC10246 and Rv1634 showed the highest expression level of 3.205 in strain CCDC10293. In four pan-sensitive clinical isolates CCDC10330, CCDC10201, CCDC10261, and CCDC10293, mmpl13b showed the lowest expression levels from 0.113 to 0.159. In six pan-sensitive clinical isolates CCDC10328, CCDC10238, CCDC10239, CCDC10231, CCDC10246, and CCDC10255, Rv3239c showed the lowested expression levels from 0.060 to 0.178. In this study, we examined the expressional differences between MDR isolates and pan-sensitive isolates without drug inducement. The expression levels of 11 genes (efpA, Rv0849, Rv1250, P55 (Rv1410c), Rv1634, Rv2994, stp, Rv2459, pstB, drrA, and drrB) were significantly higher (P < 0.05) in nine MDR isolates than in 10 pan-sensitive isolates (Table 4). We also found that the expression of three genes (Rv1877, Rv2265, and mmpL13a) was significantly lower (P < 0.05) in nine MDR isolates than in 10 pan-sensitive isolates. Li et al. reported that deleting the closest homologs of mmpL13a-mmpL13b (Rv1145-Rv1146) in M. smegmatis did not alter the drug susceptibility, whereas deleting the Rv1877 homolog resulted in increased susceptibility to ethidium bromide, acriflavine, and erythromycin [38]. These results suggested that the role of these efflux pumps is probably not to pump out anti-tubercular drugs but, rather, that they regulate the intracellular levels of nutrients and co-factors. The differences between MDR and pan-sensitive isolates suggest that quantifying the expression levels of M. tuberculosis efflux pump genes may be a new method to diagnose resistant tuberculosis and decide whether combining efflux pump inhibitors to anti-tubercular drugs would be effective to treat resistant tuberculosis.
Table 4

Relative expression levels (2-ΔCT value) of drug efflux genes of nine MDR M. tuberculosis isolates and 10 pan-sensitive isolates.

GenePan-sensitive groupMDR group
Median value25%–75% valueMedian value25%–75% value
efpA a 1.390.56–2.546.495.29–11.06
emrB 0.960.81–1.090.790.64–1.45
Rv0849 a 0.370.27–0.281.580.94–2.73
Rv1250 a 1.910.80–3.437.745.04–10.00
tap (Rv1258c)0.760.65–1.391.150.41–1.34
P55 (Rv1410c) a 0.980.64–1.302.011.62–5.51
Rv1634 b 0.360.25–0.430.540.40–1.69
Rv2994 a 0.470.37–0.561.450.89–2.22
Rv1877 b 0.550.48–0.720.340.18–0.49
stp a 0.680.44–0.781.301.21–3.70
jefA (Rv2459) a 0.930.78–1.125.374.42–19.32
Rv2265 a 0.340.24–0.520.060.04–0.27
Rv2456 0.480.32–0.680.210.14–0.53
Rv3239 0.140.11–0.170.170.06–0.22
mmpL13a b 0.520.29–0.690.200.10–0.50
mmpL13b 0.170.13–0.230.200.16–0.41
pstB a 0.650.55–1.153.292.26–5.98
drrA a 3.521.54–5.249.466.06–15.22
drrB a 1.120.79–1.503.812.83–7.12
mmr 0.230.19–0.290.350.23–0.47

aSignificant differences between the MDR and pan-sensitive groups (P < 0.01)

bSignificant differences between the MDR and pan-sensitive groups (P < 0.05).

aSignificant differences between the MDR and pan-sensitive groups (P < 0.01) bSignificant differences between the MDR and pan-sensitive groups (P < 0.05).

Conclusion

Efflux pumps may play an important role in INH acquired resistance in MDR M. tuberculosis, especially in strains without mutations in katG, inhA, and oxyR-ahpC, which are associated with INH resistance. The basal expressional differences of some drug efflux pump genes between MDR and pan-sensitive isolates may be helpful to diagnose and treat resistant tuberculosis. However, we acknowledge that we were unable to demonstrate a direct relationship between the resistance level of INH and/or RIF and the activation of specific genes. Further efforts are required to elucidate the actual roles of drug efflux pumps in the drug resistance of M. tuberculosis.

Primers used to amplify and sequence rpoB, katG, inhA, and oxyR-ahpC mutations.

(DOCX) Click here for additional data file.

Primers used in this study to quantify gene expression.

(DOCX) Click here for additional data file.

The relative expression levels (2-△CT value) of each gene of 20 strains.

(XLSX) Click here for additional data file.
  43 in total

1.  High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001.

Authors:  Igor Mokrousov; Olga Narvskaya; Tatiana Otten; Elena Limeschenko; Lidia Steklova; Boris Vyshnevskiy
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

4.  Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.

Authors:  L J Piddock; K J Williams; V Ricci
Journal:  J Antimicrob Chemother       Date:  2000-02       Impact factor: 5.790

5.  Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis.

Authors:  Joanna C Betts; Alistair McLaren; Mark G Lennon; Fiona M Kelly; Pauline T Lukey; Steve J Blakemore; Ken Duncan
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 6.  Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis.

Authors:  P J Brennan
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131

7.  Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis.

Authors:  Baisakhee Saha Choudhuri; Sanjib Bhakta; Rajib Barik; Joyoti Basu; Manikuntala Kundu; Parul Chakrabarti
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

8.  Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv.

Authors:  Jean-Christophe Camus; Melinda J Pryor; Claudine Médigue; Stewart T Cole
Journal:  Microbiology       Date:  2002-10       Impact factor: 2.777

9.  The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis.

Authors:  Edda De Rossi; Patrizio Arrigo; Marco Bellinzoni; Pedro A E Silva; Carlos Martín; José A Aínsa; Paola Guglierame; Giovanna Riccardi
Journal:  Mol Med       Date:  2002-11       Impact factor: 6.354

Review 10.  The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.

Authors:  A Somoskovi; L M Parsons; M Salfinger
Journal:  Respir Res       Date:  2001-04-05
View more
  27 in total

1.  Deregulation of Genes Associated with Alternate Drug Resistance Mechanisms in Mycobacterium tuberculosis.

Authors:  Kalpana Sriraman; Kayzad Nilgiriwala; Dhananjaya Saranath; Anirvan Chatterjee; Nerges Mistry
Journal:  Curr Microbiol       Date:  2017-11-16       Impact factor: 2.188

2.  The Mycobacterial Efflux Pump EfpA Can Induce High Drug Tolerance to Many Antituberculosis Drugs, Including Moxifloxacin, in Mycobacterium smegmatis.

Authors:  Deepika Rai; Sarika Mehra
Journal:  Antimicrob Agents Chemother       Date:  2021-08-23       Impact factor: 5.191

Review 3.  Mycobacterium tuberculosis Major Facilitator Superfamily Transporters.

Authors:  Ping Li; Yinzhong Gu; Jiang Li; Longxiang Xie; Xue Li; Jianping Xie
Journal:  J Membr Biol       Date:  2017-08-29       Impact factor: 1.843

Review 4.  Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis.

Authors:  Sander N Goossens; Samantha L Sampson; Annelies Van Rie
Journal:  Clin Microbiol Rev       Date:  2020-10-14       Impact factor: 26.132

5.  Targeting redox heterogeneity to counteract drug tolerance in replicating Mycobacterium tuberculosis.

Authors:  Richa Mishra; Sakshi Kohli; Nitish Malhotra; Parijat Bandyopadhyay; Mansi Mehta; MohamedHusen Munshi; Vasista Adiga; Vijay Kamal Ahuja; Radha K Shandil; Raju S Rajmani; Aswin Sai Narain Seshasayee; Amit Singh
Journal:  Sci Transl Med       Date:  2019-11-13       Impact factor: 17.956

Review 6.  New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria.

Authors:  Mohammad J Nasiri; Mehri Haeili; Mona Ghazi; Hossein Goudarzi; Ali Pormohammad; Abbas A Imani Fooladi; Mohammad M Feizabadi
Journal:  Front Microbiol       Date:  2017-04-25       Impact factor: 5.640

7.  Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis.

Authors:  Diana Machado; Tatiane S Coelho; João Perdigão; Catarina Pereira; Isabel Couto; Isabel Portugal; Raquel De Abreu Maschmann; Daniela F Ramos; Andrea von Groll; Maria L R Rossetti; Pedro A Silva; Miguel Viveiros
Journal:  Front Microbiol       Date:  2017-04-27       Impact factor: 5.640

Review 8.  Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections.

Authors:  Upal Roy; Paul Barber; Yuk-Ching Tse-Dinh; Elena V Batrakova; Debasis Mondal; Madhavan Nair
Journal:  Front Microbiol       Date:  2015-09-17       Impact factor: 5.640

9.  Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance.

Authors:  Christopher A Desjardins; Keira A Cohen; Vanisha Munsamy; Thomas Abeel; Kashmeel Maharaj; Bruce J Walker; Terrance P Shea; Deepak V Almeida; Abigail L Manson; Alex Salazar; Nesri Padayatchi; Max R O'Donnell; Koleka P Mlisana; Jennifer Wortman; Bruce W Birren; Jacques Grosset; Ashlee M Earl; Alexander S Pym
Journal:  Nat Genet       Date:  2016-04-11       Impact factor: 38.330

Review 10.  Diversity and evolution of drug resistance mechanisms in Mycobacterium tuberculosis.

Authors:  Mashael Al-Saeedi; Sahal Al-Hajoj
Journal:  Infect Drug Resist       Date:  2017-10-13       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.